These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 24825641)
1. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. Moulton CA; Gu CS; Law CH; Tandan VR; Hart R; Quan D; Fairfull Smith RJ; Jalink DW; Husien M; Serrano PE; Hendler AL; Haider MA; Ruo L; Gulenchyn KY; Finch T; Julian JA; Levine MN; Gallinger S JAMA; 2014 May; 311(18):1863-9. PubMed ID: 24825641 [TBL] [Abstract][Full Text] [Related]
2. A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastases. Daza JF; Solis NM; Parpia S; Gallinger S; Moulton CA; Belley-Cote EP; Levine MN; Serrano PE Eur J Surg Oncol; 2019 Aug; 45(8):1341-1348. PubMed ID: 30928334 [TBL] [Abstract][Full Text] [Related]
3. Positron Emission Tomography Combined With Computed Tomography vs. No Positron Emission Tomography Combined With Computed Tomography for the Management of Patients With Resectable Colorectal Cancer Liver Metastases and Synchronous Extrahepatic Disease. Serrano PE; Gu CS; Moulton CA; Gallinger S Am Surg; 2021 Sep; 87(9):1431-1437. PubMed ID: 33345573 [TBL] [Abstract][Full Text] [Related]
4. Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography. Abbadi RA; Sadat U; Jah A; Praseedom RK; Jamieson NV; Cheow HK; Whitley S; Ford HE; Wilson CB; Harper SJ; Huguet EL J Surg Oncol; 2014 Sep; 110(3):313-9. PubMed ID: 24737685 [TBL] [Abstract][Full Text] [Related]
5. Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial. Metser U; Halankar J; Langer D; Mohan R; Hussey D; Hadas M; Tamir S Ann Nucl Med; 2017 Feb; 31(2):153-162. PubMed ID: 27848159 [TBL] [Abstract][Full Text] [Related]
6. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421 [TBL] [Abstract][Full Text] [Related]
7. Effect of PET-CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long-term results of a randomized controlled trial. Serrano PE; Gu CS; Moulton CA; Husien M; Jalink D; Martel G; Tsang ME; Hallet J; McAlister V; Gallinger S; Levine M J Surg Oncol; 2020 May; 121(6):1001-1006. PubMed ID: 32034769 [TBL] [Abstract][Full Text] [Related]
8. The role of FDG-PET in the selection of patients with colorectal liver metastases. Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Glazer ES; Beaty K; Abdalla EK; Vauthey JN; Curley SA Arch Surg; 2010 Apr; 145(4):340-5; discussion 345. PubMed ID: 20404283 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery. Lee HS; Kim HO; Hong YS; Kim TW; Kim JC; Yu CS; Kim JS J Nucl Med; 2014 Apr; 55(4):582-9. PubMed ID: 24549284 [TBL] [Abstract][Full Text] [Related]
12. Recurrent tumor after resection of hepatic metastases from colorectal carcinoma: location and time of discovery as determined by CT. Harned RK; Chezmar JL; Nelson RC AJR Am J Roentgenol; 1994 Jul; 163(1):93-7. PubMed ID: 8010256 [TBL] [Abstract][Full Text] [Related]
13. Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial. Serrano PE; Gafni A; Gu CS; Gulenchyn KY; Julian JA; Law C; Hendler AL; Moulton CA; Gallinger S; Levine MN J Oncol Pract; 2016 Jul; 12(7):e765-74. PubMed ID: 27328792 [TBL] [Abstract][Full Text] [Related]